Wolfe Research Raises Price Target for Pfizer Amid Ongoing COVID Uncertainty
On May 14, Wolfe Research analyst Alexandria Hammond raised its price target on Pfizer (PFE) to $26 from $25 but maintained an Underperform rating due to ongoing uncertainty in the company's pandemic-related business. The firm cited a revenue beat and long-term growth potential tied to Vyndamax exclusivity through 2031 as factors behind the increase.
Tickers: $PFE
Topics: Dividend Strategy Earnings Guidance Pfizer Vyndamax Wolfe Research